CoChat

An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries

Open access

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

PURPOSE: Denosumab (administered via subcutaneous injection) demonstrated superior efficacy versus the intravenously administered zoledronic acid in the prevention of skeletal-related events in an integrated analysis of three head-to-head phase III trials in patients with bone metastases secondary to solid tumors. To date, no studies have evaluated treatment administration duration endpoints of these two agents. METHODS: A multinational, multi-site, observational time and motion study conducted in 10 day oncology units (DOUs) across Belgium, Germany, and Italy. Observations of process time included task time and active healthcare professional (HCP) time for pre-defined tasks. Patient time measurements included entering/exiting the DOU, treatment room, and treatment chair or examination table. RESULTS: A total of 189 patients were enrolled (82 received zoledronic acid and 107 received denosumab) and 238 observations were recorded (104 for zoledronic acid and 134 for denosumab). Mean total task time was reduced by 81% when denosumab was used versus zoledronic acid (8.4 versus 44.2 min; p < 0.0001; pooled analysis across all countries). Pooled estimates for active HCP time were 12.2 min for zoledronic acid and 6.9 min for denosumab (44% reduction; p < 0.0001). CONCLUSIONS: In the countries studied, using denosumab compared with zoledronic acid reduced total task time and active HCP time. Thus, HCPs have more time to dedicate to other patients or care activities. An ability to increase the volume of appointments within DOUs could reduce waiting lists in sites operating at full capacity and increase overall productivity and efficiency in hospital processes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00520-017-3697-5

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Process time variables per treatment administration. a mean task time and b mean active HCP time * p < 0.0001. Note for panel b: The ‘Patient arrival and registration’ task was typically the same for Zol and Dmab and pooled estimates were comparable. For one site in Belgium, the ‘Installation of peripheral catheter’ task was also performed in patients receiving Dmab because of the need for blood sampling; pre-medication was also sometimes given. Active patient monitoring during infusion, post-infusion and post-injection was rare in most centres. The ‘Preparation of Dmab SC syringe and injection’ task differed across centres in terms of time required and the sub-tasks involved. Dmab denosumab, HCP healthcare professional, IV intravenous, SC subcutaneous, Zol zoledronic acid
Fig. 1 Process time variables per treatment administration. a mean task time and b mean active HCP time * p < 0.0001. Note for panel b: The ‘Patient arrival and registration’ task was typically the same for Zol and Dmab and pooled estimates were comparable. For one site in Belgium, the ‘Installation of peripheral catheter’ task was also performed in patients receiving Dmab because of the need for blood sampling; pre-medication was also sometimes given. Active patient monitoring during infusion, post-infusion and post-injection was rare in most centres. The ‘Preparation of Dmab SC syringe and injection’ task differed across centres in terms of time required and the sub-tasks involved. Dmab denosumab, HCP healthcare professional, IV intravenous, SC subcutaneous, Zol zoledronic acidCC BY-NC · PubMed Central
Fig. 2 Patient time variables per treatment administration. a Mean drug administration duration, b mean patient chair time and c mean patient treatment room time. * p < 0.0001. Dmab denosumab, IV intravenous, SC subcutaneous, Zol zoledronic acid
Fig. 2 Patient time variables per treatment administration. a Mean drug administration duration, b mean patient chair time and c mean patient treatment room time. * p < 0.0001. Dmab denosumab, IV intravenous, SC subcutaneous, Zol zoledronic acidCC BY-NC · PubMed Central
Fig. 3 Mean patient DOU time per treatment administration. *p < 0.0001; **p = 0.0228. Notes: One site in Germany reported a mean of 15 min (across both Zol and Dmab) between arrival at DOU and entry in treatment room, due to blood sampling and control of vital parameters, and a mean of 30 min between exit of treatment room and exit of DOU because of a physician consultation. In Belgium, one site reported a mean of 35 min between arrival at DOU and entry in treatment room, due to a physician consultation, while in another site this task took on average 100 min because of blood sampling and physician consultation. In Italy, the majority of sites performed a physician consultation before drug administration; in one site, blood sampling was performed on treatment day and patients waited for the laboratory results before entering the treatment room. Dmab denosumab, DOU day oncology unit, IV intravenous, SC subcutaneous, Zol zoledronic acid
Fig. 3 Mean patient DOU time per treatment administration. *p < 0.0001; **p = 0.0228. Notes: One site in Germany reported a mean of 15 min (across both Zol and Dmab) between arrival at DOU and entry in treatment room, due to blood sampling and control of vital parameters, and a mean of 30 min between exit of treatment room and exit of DOU because of a physician consultation. In Belgium, one site reported a mean of 35 min between arrival at DOU and entry in treatment room, due to a physician consultation, while in another site this task took on average 100 min because of blood sampling and physician consultation. In Italy, the majority of sites performed a physician consultation before drug administration; in one site, blood sampling was performed on treatment day and patients waited for the laboratory results before entering the treatment room. Dmab denosumab, DOU day oncology unit, IV intravenous, SC subcutaneous, Zol zoledronic acidCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 12

Metadata

Authors
Body, J.-J., Gatta, F., De Cock, E., Tao, S., Kritikou, P., Wimberger, P., Mebis, J., Peeters, M., Pedrazzoli, P., Caraceni, A., Adamo, V., & Hechmati, G.
Affiliations
  • Université Libre de Bruxelles (BE)
  • Amgen (Switzerland) (CH)
  • University Hospital Carl Gustav Carus (DE)
  • Jessa Hospital (BE)
  • Antwerp University Hospital (BE)
  • Policlinico San Matteo Fondazione (IT)
  • Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
  • University of Messina (IT)
Corresponding author
Body, Jean-Jacques
Venue
Supportive Care in Cancer
Published
2017-04-21
Volume
25
Issue
9
Pages
2823-2832
ISSN
  • 0941-4355 (ISSN-L)
  • 1433-7339
OpenAlex
W2606662033
Cited by
11
References
24
Citations by year
2026: 1 · 2025: 1 · 2024: 1 · 2023: 3 · 2022: 2 · 2020: 2 · 2019: 1
FWCI
0.36
Type
journal article
Language
en
Open access
Locations
  • Supportive Care in Cancer (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
  • Document Server@UHasselt (UHasselt) (submittedVersion, other-oa)
Funders
Amgen (Europe) GmbH
Topics
  • Health Sciences › Medicine › Oncology › Bone health and treatments
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Health Sciences › Medicine › Surgery › Management of metastatic bone disease
Keywords
denosumab, zoledronic acid, bone metastasis, subcutaneous injection, intravenous infusion, skeletal-related events, waiting lists
MeSH terms
Denosumab, Zoledronic Acid, Bone Neoplasms, Diphosphonates, Europe, Female, Humans, Imidazoles, Infusions, Intravenous, Injections, Subcutaneous, Male, Time and Motion Studies, Bone Density Conservation Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries. https://app.cochat.ai/papers/10.1007/s00520-017-3697-5
The paper
Body, J.-J., Gatta, F., De Cock, E., Tao, S., Kritikou, P., Wimberger, P., Mebis, J., Peeters, M., Pedrazzoli, P., Caraceni, A., Adamo, V., & Hechmati, G. (2017). An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries. Supportive Care in Cancer. https://doi.org/10.1007/s00520-017-3697-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.